{"filing":{"accession_number":"0001401914-26-000032","cik":"0001401914","ticker":"DARE","company_name":"Dare Bioscience, Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"dare-20260611.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191426000032/dare-20260611.htm"},"events":[{"id":10817,"run_id":9491,"accession_number":"0001401914-26-000032","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Dare Bioscience held a stockholder meeting on June 11, 2026, with voting results on eight proposals including director elections, auditor ratification, say-on-pay approval, and an amendment to the 2022 Stock Incentive Plan increasing available shares by 1,500,000.","company_name":"Dare Bioscience, Inc.","ticker":"DARE","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":7227,"accession_number":"0001401914-26-000032","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2022 Stock Incentive Plan increasing available shares by 1,500,000, which is a compensatory arrangement affecting equity grants to officers and directors. While Item 5.07 reports the vote results, Item 5.02 here focuses on the substantive compensation plan amendment itself, making exec_compensation the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:19:47.962408+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7228,"accession_number":"0001401914-26-000032","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder meeting results held on June 11, 2026. The filing reports voting outcomes for eight proposals including director elections (Proposal 1), auditor ratification (Proposal 2), say-on-pay approval (Proposal 3), equity plan amendment (Proposal 6), and authorization for equity issuance under a Lincoln Park Capital line (Proposal 5). The detailed vote tallies and board determinations (e.g., annual say-on-pay frequency) are material to investors assessing governance and capital structure decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:19:47.962408+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7227,"accession_number":"0001401914-26-000032","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2022 Stock Incentive Plan increasing available shares by 1,500,000, which is a compensatory arrangement affecting equity grants to officers and directors. While Item 5.07 reports the vote results, Item 5.02 here focuses on the substantive compensation plan amendment itself, making exec_compensation the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:19:47.962408+00:00","company_name":"Dare Bioscience, Inc.","ticker":"DARE","filing_date":"2026-06-12"},{"id":7228,"accession_number":"0001401914-26-000032","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder meeting results held on June 11, 2026. The filing reports voting outcomes for eight proposals including director elections (Proposal 1), auditor ratification (Proposal 2), say-on-pay approval (Proposal 3), equity plan amendment (Proposal 6), and authorization for equity issuance under a Lincoln Park Capital line (Proposal 5). The detailed vote tallies and board determinations (e.g., annual say-on-pay frequency) are material to investors assessing governance and capital structure decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:19:47.962408+00:00","company_name":"Dare Bioscience, Inc.","ticker":"DARE","filing_date":"2026-06-12"}]}